SAN DIEGO–(BUSINESS WIRE)–Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has been awarded a $2.5 million Small Business Innovation Research (SBIR) Phase II grant (R44GM154585) from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH). The award
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
